May 10, 2022 / 11:00PM GMT
Geoffrey Christopher Meacham - BofA Securities, Research Division - Research Analyst
The afternoon session of the BofA Healthcare Conference. My name is Geoff Meacham. I'm the senior biopharma analyst here at BofA. We're thrilled today to have Vanda Pharmaceuticals, and speaking on behalf of Vanda is CFO, Kevin Moran. Kevin?
Kevin Patrick Moran - Vanda Pharmaceuticals Inc. - Senior VP, CFO & Treasurer
Good afternoon, everyone, and thank you very much, Geoff, for the introduction and the invitation. Very excited to share our progress with everyone here.
Great. Here are our forward-looking statements that we'd like for folks to review and be aware of.
So Vanda has 2 commercialized products, HETLIOZ and Fanapt. HETLIOZ comes in 2 forms, oral capsules and liquid formulation. Oral capsules are approved in the U.S. and Europe for the treatment of Non-24-hour sleep wake disorder. HETLIOZ oral capsules and HETLIOZ LQ, the liquid formulation, are also approved for the treatment of nighttime sleep disturbances in adults and children, respectively,
Vanda Pharmaceuticals Inc at Bank of America Healthcare Conference Transcript
Mar 08, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers